Skip to Main Content

Paper Details

Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.
Neuro Oncol
4
2023
B-cell lymphomas, C-reactive protein, CAR, CAR T-, CAR T-cell, CAR T-cells, CD19, CD19-directed chimeric antigen receptor T-cells, CNS, CNS lymphoma, CRP, Chimeric antigen receptor, Chimeric antigen receptor (CAR) T-cells, Dexamethasone, ICANS, Neurotoxicity, PCNSL, SCNSL, antigen receptor, central nervous system lymphoma, chimeric, fever, ibrutinib, immune effector cell-associated neurotoxicity syndrome, patient, patients, primary CNS lymphoma, secondary CNS lymphoma
Author NameAffiliation
Isabel Arrillaga-RomanyMassachusetts General Hospital Cancer Center, Harvard Medical School
Nancy WangMassachusetts General Hospital Cancer Center, Harvard Medical School
Maria Martinez-LageMassachusetts General Hospital, Harvard Medical School
Maria Martinez-LageMassachusetts General Hospital, Harvard Medical School
Brian V NahedMassachusetts General Hospital, Harvard Medical School
Areej El-JawahriMassachusetts General Hospital Cancer Center, Harvard Medical School
  • 1 - 6

Datasets

Release 1.2